Any current/future new fundraising through debt or equity?

For future fundraising related to projects such as the PPP model for IV plants, the company will decide based on the capital required. If the investment needed is around INR 10 crores, funding may be done through internal accruals or small loans. For larger projects requiring INR 30-40 crores, the company may raise funds from the market (equity or debt). No specific ongoing or planned equity fundraise was mentioned as of the November 2025 call. The company is working on meeting parameters for NSE listing, but it will take 2-3 more quarters, indicating no immediate equity raising via public mar

Any current/future capex/capital investment/strategic investment?

In H1 FY '26, Sanjivani Paranteral Limited undertook a capex of INR 1.04 crores. The company is modernizing its facilities, incorporating AI to enhance efficiency and cost-effectiveness. Development of import alternatives at the Pune plant is on track, with test licenses in place; products expected in the next 2-3 quarters. The Pune plant has started commercial production recently and is expected to contribute INR 90-110 crores revenue on full-year operation, hitting optimal capacity by Q2 FY '27. Future PPP (Public-Private Partnership) models are being explored; depending on investment size,

Future growth expectations in sales/revenue/volumes?

The company expects a minimum of 10% sales growth from the previous year, rebounding from recent disruptions. Pune plant to start contributing commercially from Q3 FY '26, with full-year revenue potential of INR 90-110 crores. Optimal capacity utilization of the Pune plant expected by Q2 FY '27, potentially contributing INR 20-25 crores quarterly. Base business growth projected at 15-20% for the next year (FY '27), with total revenue expected around INR 150 crores. Alevia Healthcare joint venture is forecasted to contribute INR 1-1.5 crores to the bottom line in FY '26 and expected to

Future growth expectations in earnings/operating earnings/profits/EPS?

The company expects a minimum of 10% sales growth for FY '26 compared to the previous year. Alevia Healthcare (European nutraceutical venture) is projected to contribute around INR 1-1.5 crores to the bottom line in FY '26, with a potential 100% growth to INR 3-3.5 crores or more in FY '27. The Pune IV plant venture is expected to generate INR 90-110 crores in a full year, with capacity utilization targeted by Q2 FY '27 and quarterly revenues of INR 20-25 crores from that point. EBITDA margins and profitability may improve as new ventures ramp up and operational efficiencies increase thr

Current/ Expected Orderbook/ Pending Orders?

The Pune plant has a "very good healthy order book" in place, with commercial production started and business commencing from Q3 FY '26. Orders for the Pune plant come from semi-government, government institutions, and exports to 3-4 established geographies. Specific quantities of the Pune plant’s order book were not disclosed, with quantification to be provided later. Orders worth approximately INR 1 crore were held back due to local unrest in Nepal but have since been dispatched. Order books are reported to be good, supporting improved sales in the next two quarters. There is a bac

IN US

Sale is live|00:00:00left today

Sanjivani Paranteral LtdQ3 FY25Pharmaceuticals & Biotechnology

Sanjivani Paranteral Ltd Q3 FY25 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹147P/E: 24.0Market Cap: ₹197 CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

Yes

Order

Yes

Capex

Yes

3 of 5 growth signals are positive.

Full analysis

Revenue guidance

Category 3

→The company expects a minimum of 10% sales growth from the previous year, rebounding from recent disruptions.
→Pune plant to start contributing commercially from Q3 FY '26, with full-year revenue potential of INR 90-110 crores.
→Optimal capacity utilization of the Pune plant expected by Q2 FY '27, potentially contributing INR 20-25 crores quarterly.
→Base business growth projected at 15-20% for the next year (FY '27), with total revenue expected around INR 150 crores.
→Alevia Healthcare joint venture is forecasted to contribute INR 1-1.5 crores to the bottom line in FY '26 and expected to grow at least 100% in FY '27 (INR 3-3.5 crores+).
→The company aims to maintain flexibility with supply chain strategies to reduce timelines and respond to premium pricing opportunities.
→Long-term growth targeted despite near-term regulatory and external market challenges, focusing on quality and diversified markets.

Margin guidance

Category 3

→The company expects a minimum of 10% sales growth for FY '26 compared to the previous year.
→Alevia Healthcare (European nutraceutical venture) is projected to contribute around INR 1-1.5 crores to the bottom line in FY '26, with a potential 100% growth to INR 3-3.5 crores or more in FY '27.
→The Pune IV plant venture is expected to generate INR 90-110 crores in a full year, with capacity utilization targeted by Q2 FY '27 and quarterly revenues of INR 20-25 crores from that point.
→EBITDA margins and profitability may improve as new ventures ramp up and operational efficiencies increase through AI and modernization.
→Earnings could benefit from reduced employee costs due to automation, and new government price revisions for IV products may be positive.
→Overall, management is optimistic about sustainable and healthy growth across all business verticals in upcoming quarters.

3 more insights locked — sign up free to unlock

Fundraise plans

Yes

→For future fundraising related to projects such as the PPP model for IV plants, the company will decide based on the capital required.
→If the investment needed is around INR 10 crores, funding may be done through internal accruals or small loans.
→For larger projects requiring INR 30-40 crores, the company may raise funds from the market (equity or debt).
→No specific ongoing or planned equity fundraise was mentioned as of the November 2025 call.
→The company is working on meeting parameters for NSE listing, but it will take 2-3 more quarters, indicating no immediate equity raising via public markets currently.
→Overall, fundraising approach is opportunity-driven, with preference for internal accruals or loans for smaller needs and market raising for bigger investments.

Order book

Yes

→The Pune plant has a "very good healthy order book" in place, with commercial production started and business commencing from Q3 FY '26.
→Orders for the Pune plant come from semi-government, government institutions, and exports to 3-4 established geographies.
→Specific quantities of the Pune plant’s order book were not disclosed, with quantification to be provided later.
→Orders worth approximately INR 1 crore were held back due to local unrest in Nepal but have since been dispatched.
→Order books are reported to be good, supporting improved sales in the next two quarters.
→There is a backlog of held shipments due to regulatory scrutiny, now being cleared and shipped, contributing to a positive outlook for Q3 and Q4.
→The company is working on multiple opportunities, including government PPP ventures and international markets registrations, which may add orders soon.

Capex plans

Yes

→In H1 FY '26, Sanjivani Paranteral Limited undertook a capex of INR 1.04 crores.
→The company is modernizing its facilities, incorporating AI to enhance efficiency and cost-effectiveness.
→Development of import alternatives at the Pune plant is on track, with test licenses in place; products expected in the next 2-3 quarters.
→The Pune plant has started commercial production recently and is expected to contribute INR 90-110 crores revenue on full-year operation, hitting optimal capacity by Q2 FY '27.
→Future PPP (Public-Private Partnership) models are being explored; depending on investment size, funding may come from internal accruals, small loans, or external market fundraising.
→Continuous upgradation in facilities, capex, and training is planned to meet tightening regulatory standards, especially for export markets.

How does Sanjivani Paranteral Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

1Sanjivani Paranteral Ltd

Rev 3Mar 3

See full Pharmaceuticals & Biotechnology sector rankings

Want more stocks like Sanjivani Paranteral Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio